Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Código QR

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Guardado en:

Detalles Bibliográficos
Autores principales:	Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0b0846e51ee743ccaa771226ef3e7e54
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Motohiro Tamiya, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Xiaoying Zhang
Publicado: (2021)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Bin Zou, et al.
Publicado: (2017)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021)

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko B, et al.
Publicado: (2017)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yaning Yang, et al.
Publicado: (2021)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan YH, et al.
Publicado: (2018)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
por: Jeng-Sen Tseng, et al.
Publicado: (2014)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
por: Po-Hsin Lee, et al.
Publicado: (2021)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Tereza Vaclova, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Qian Shen, et al.
Publicado: (2021)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Jana Fassunke, et al.
Publicado: (2018)

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation
por: Wang G, et al.
Publicado: (2019)

Acta Nº790
por: Banco Central de Chile
Publicado: (2019)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Rajeswara Rao Arasada, et al.
Publicado: (2018)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Rong Wang, et al.
Publicado: (2020)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang SS, et al.
Publicado: (2021)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Aliki Ntzifa, et al.
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
por: Simona Taverna, et al.
Publicado: (2017)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa S, et al.
Publicado: (2021)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Hyun Woo Lee, et al.
Publicado: (2020)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
por: João M. Fernandes Neto, et al.
Publicado: (2020)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device
por: Xian-Ying Li, et al.
Publicado: (2017)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Kamrine E. Poels, et al.
Publicado: (2021)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)